Felbinac
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB07477 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 35 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | brachyolmia-amelogenesis imperfecta syndrome | KG + DL |
| 2 | acromesomelic dysplasia, Hunter-Thompson type | KG + DL |
| 3 | myosclerosis | KG + DL |
| 4 | brachyolmia | KG + DL |
| 5 | pseudoachondroplasia | KG + DL |
| 6 | spondyloarthropathy, susceptibility to | KG + DL |
| 7 | rheumatoid nodulosis | KG + DL |
| 8 | combined immunodeficiency due to moesin deficiency | KG + DL |
| 9 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | KG + DL |
| 10 | juvenile idiopathic arthritis | KG + DL |
| 11 | juvenile chronic polyarthritis | KG + DL |
| 12 | juvenile arthritis due to defect in LACC1 | KG + DL |
| 13 | ankylosing spondylitis | KG + DL |
| 14 | hypotrichosis simplex of the scalp | KG + DL |
| 15 | hypermobility of coccyx | KG + DL |
| 16 | rheumatoid vasculitis | KG + DL |
| 17 | congenital hypotrichosis milia | KG + DL |
| 18 | polyarticular juvenile rheumatoid arthritis | KG + DL |
| 19 | Kummell disease | KG + DL |
| 20 | inflammatory spondylopathy | KG + DL |
| 21 | diffuse alopecia areata | KG + DL |
| 22 | rheumatoid arthritis | KG + DL |
| 23 | WHIM syndrome | KG + DL |
| 24 | vertebral disease | KG + DL |
| 25 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 26 | brachydactyly-syndactyly syndrome | KG + DL |
| 27 | alopecia | KG + DL |
| 28 | mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency | KG + DL |
| 29 | spondyloarthropathy | KG + DL |
| 30 | leukoplakia | KG + DL |
| 31 | intracranial embolism | KG + DL |
| 32 | heparin cofactor 2 deficiency | KG + DL |
| 33 | psoriasis-related juvenile idiopathic arthritis | KG + DL |
| 34 | Behr syndrome | KG + DL |
| 35 | factor 5 excess with spontaneous thrombosis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.